Trial
NCT04329949
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Corcept Therapeutics
Collaborators
—
Condition
Metastatic Pancreatic Ductal Adenocarcinoma
Intervention
Relacorilant, 100 mg and 25 mg
Why stopped
The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-18